Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study

Journal of the National Cancer Institute
Arnold L PotoskyLinda C Harlan

Abstract

Men treated for clinically localized prostate cancer with either radical prostatectomy or external beam radiotherapy usually survive many years with the side effects of these treatments. We present treatment-specific quality-of-life outcomes for prostate cancer patients 5 years after initial diagnosis. The cohort consisted of men aged 55-74 years who were newly diagnosed with clinically localized prostate cancer in 1994-1995 and were treated with radical prostatectomy (n = 901) or external beam radiotherapy (n = 286). We used clinical and quality-of-life data previously collected at the time of diagnosis (i.e., baseline) and at the 2-year follow-up and data newly collected at 5 years after diagnosis to compare urinary, bowel, and sexual function and to examine temporal changes in those functions. Odds ratios (ORs) and adjusted percentages were calculated by logistic regression. All statistical tests were two-sided. At 5 years after diagnosis, overall sexual function declined in both groups to approximately the same level. However, at 5 years after diagnosis, erectile dysfunction was more prevalent in the radical prostatectomy group than in the external beam radiotherapy group (79.3% versus 63.5%; OR = 2.5, 95% confidence interv...Continue Reading

References

Feb 12, 1998·Annals of Internal Medicine·D B Rubin
Oct 21, 1999·Journal of the National Cancer Institute·A L PotoskyM S Litwin
Jan 6, 2000·Journal of the National Cancer Institute·S P ShriverJ M Siegfried
Jan 27, 2000·JAMA : the Journal of the American Medical Association·J L StanfordA L Potosky
Jun 24, 2000·JAMA : the Journal of the American Medical Association·F J FowlerM J Barry
Feb 17, 2001·Psycho-oncology·J Brennan
Mar 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J B MadalinskaF H Schröder
Apr 25, 2001·Biometrics·B I Graubard, E L Korn
May 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A S HamiltonA L Potosky
Sep 5, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A L PotoskyR M Hoffman
Jan 12, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John T WeiMartin G Sanda
Sep 13, 2002·The New England Journal of Medicine·Lars HolmbergUNKNOWN Scandinavian Prostatic Cancer Group Study Number 4
Sep 13, 2002·The New England Journal of Medicine·Gunnar SteineckUNKNOWN Scandinavian Prostatic Cancer Group Study Number 4
Oct 5, 2002·Cancer·Leslie R SchoverPatrick A Kupelian
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David F PensonJanet L Stanford
Apr 11, 2003·The Journal of Urology·David F PensonNeil K Aaronson
Jul 3, 2003·Journal of the National Cancer Institute·Matthew R CooperbergPeter R Carroll
Oct 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James A TalcottAnthony V D'Amico

❮ Previous
Next ❯

Citations

Mar 1, 2012·Archives of Internal Medicine·Ann C RaldowCary P Gross
Jul 10, 2008·JAMA : the Journal of the American Medical Association·Grace L Lu-YaoSiu-Long Yao
Feb 24, 2012·Der Urologe. Ausg. A·S AufderklammC Schwentner
Jul 3, 2008·World Journal of Urology·Stephen S ConnollyAnthony Atala
Aug 16, 2008·World Journal of Urology·Hashim Uddin Ahmed, Mark Emberton
Nov 22, 2011·World Journal of Urology·Andrew J Vickers, Hans Lilja
Aug 31, 2011·Cancer Causes & Control : CCC·Sara E WagnerJames R Hébert
Jul 31, 2013·International Urology and Nephrology·A L PatersonH K Sharma
Sep 22, 2011·Journal of General Internal Medicine·Karim ChamieMark S Litwin
Mar 1, 2012·Journal of General Internal Medicine·Floyd J FowlerJonathan S Skinner
Jul 24, 2008·Journal of Cancer Survivorship : Research and Practice·Neeraj K AroraJennifer Stevens
Jul 24, 2008·Journal of Cancer Survivorship : Research and Practice·Sophie D FossåAlv A Dahl
Sep 18, 2009·Journal of Cancer Survivorship : Research and Practice·Gregory P BeehlerLaura O Wray
Apr 25, 2006·Current Urology Reports·Stacy Loeb, Robert B Nadler
Jun 1, 2011·Journal of Cancer Education : the Official Journal of the American Association for Cancer Education·Gunhild Maria GjersetLene Thorsen
Jul 4, 2013·Journal of Cancer Education : the Official Journal of the American Association for Cancer Education·Melinda BallKatherine DuHamel
Sep 3, 2013·Journal of Cancer Education : the Official Journal of the American Association for Cancer Education·Alok VijDavid M Latini
May 24, 2005·Urologic Oncology·Marcus L Quek, David F Penson
Jan 23, 2009·International Journal of Impotence Research·D WittmannJ E Montie
Oct 30, 2007·Nature Clinical Practice. Oncology·Hashim Uddin AhmedMark Emberton
Feb 14, 2006·Nature Clinical Practice. Urology·Stéphane DroupyFrançois Giuliano
Jun 10, 2006·Nature Clinical Practice. Urology·Henriette MagelssenSophie D Fosså
Aug 12, 2006·Nature Clinical Practice. Urology·John L GoreMark S Litwin
Jan 13, 2006·Prostate Cancer and Prostatic Diseases·V BhatnagarR M Kaplan
Apr 26, 2013·The New England Journal of Medicine·Matthew J Resnick, David F Penson
May 13, 2005·The New England Journal of Medicine·Anna Bill-AxelsonUNKNOWN Scandinavian Prostate Cancer Group Study No. 4
Mar 20, 2009·The New England Journal of Medicine·Gerald L AndrioleUNKNOWN PLCO Project Team
Aug 17, 2012·The New England Journal of Medicine·Eveline A M HeijnsdijkHarry J de Koning
Feb 1, 2013·The New England Journal of Medicine·Matthew J ResnickDavid F Penson
Mar 26, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D J StoreyM Sharpe
Apr 7, 2009·Japanese Journal of Clinical Oncology·Chisato HamashimaTomotaka Sobue
Sep 16, 2004·Journal of the National Cancer Institute·Carlos BermejoIan M Thompson
Oct 6, 2005·Journal of the National Cancer Institute·Brenda K EdwardsLinda W Pickle
Aug 17, 2006·Journal of the National Cancer Institute·David C MillerJohn T Wei
Jun 11, 2009·Journal of the National Cancer Institute·John L GoreMark S Litwin
Jun 11, 2009·Journal of the National Cancer Institute·Pamela J Goodwin, Srikala S Sridhar
May 9, 2006·Current Opinion in Urology·Philipp Dahm
Aug 2, 2007·Cancer Nursing·Anne Katz
Apr 3, 2008·Current Opinion in Urology·Jared Cox, Christopher L Amling
Mar 5, 2009·Cancer Nursing·Joanne M Harrington, Terry A Badger

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.